The findings? Zepbound led to an average weightloss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study's findings, what sets these ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to ...
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.